Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 22

Sort by

Sort Order Select

Journal Articles

New therapies for von Willebrand disease

Pier Mannuccio Mannucci

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 590–595.

https://doi.org/10.1182/hematology.2019000368

Published: 2019

Journal Articles

Perioperative management of patients with von Willebrand disease

James S. O’Donnell, Michelle Lavin

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 604–609.

https://doi.org/10.1182/hematology.2019000065

Published: 2019

Journal Articles

New advances in the diagnosis of von Willebrand disease

Ruchika Sharma, Sandra L. Haberichter

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 596–600.

https://doi.org/10.1182/hematology.2019000064

Published: 2019

Journal Articles

Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy

Margaret V. Ragni

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 605–609.

https://doi.org/10.1182/asheducation-2017.1.605

Published: 2017

Journal Articles

What have we learned from large population studies of von Willebrand disease?

Robert R. Montgomery, Veronica H. Flood

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 670–677.

https://doi.org/10.1182/asheducation-2016.1.670

Published: 2016

Journal Articles

Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors

Paul E. Monahan

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 33–40.

https://doi.org/10.1182/asheducation-2015.1.33

Published: 2015

Journal Articles

Acquired bleeding disorders in the elderly

Rebecca Kruse-Jarres

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 231–236.

https://doi.org/10.1182/asheducation-2015.1.231

Published: 2015

Journal Articles

Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses

Birgit M. Reipert

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 372–378.

https://doi.org/10.1182/asheducation.V2014.1.372.3884771

Published: 2014

Journal Articles

Lasting power of new clotting proteins

Jerry S. Powell

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 355–363.

https://doi.org/10.1182/asheducation-2014.1.355

Published: 2014

Journal Articles

Clinical and laboratory diagnosis of VWD

Augusto B. Federici

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 524–530.

https://doi.org/10.1182/asheducation-2014.1.524

Published: 2014

Journal Articles

von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy

David Lillicrap

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 254–260.

https://doi.org/10.1182/asheducation-2013.1.254

Published: 2013

Journal Articles

The hemophilias and their clinical management

Neil Josephson

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 261–267.

https://doi.org/10.1182/asheducation-2013.1.261

Published: 2013

Journal Articles

Biological Rationale for New Drugs in the Bleeding Disorders Pipeline

Patrick F. Fogarty

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 397–404.

https://doi.org/10.1182/asheducation-2011.1.397

Published: 2011

Journal Articles

What is the Evidence for the Use of Immunomodulatory Agents to Eradicate Inhibitory Antibodies in Patients with Severe Hemophilia A Who Have Previously Failed to Respond to Immune Tolerance Induction?

Michael U. Callaghan, Patrick F. Fogarty

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 405–406.

https://doi.org/10.1182/asheducation-2011.1.405

Published: 2011

Journal Articles

Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A

Rebecca Kruse-Jarres

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 407–412.

https://doi.org/10.1182/asheducation-2011.1.407

Published: 2011

Journal Articles

Optimizing treatment of von Willebrand disease by using phenotypic and molecular data

Francesco Rodeghiero, Giancarlo Castaman, Alberto Tosetto

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 113–123.

https://doi.org/10.1182/asheducation-2009.1.113

Published: 2009

Journal Articles

Acquired Factor VIII Inhibitors: Pathophysiology and Treatment

Alice D. Ma, Daniel Carrizosa

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 432–437.

https://doi.org/10.1182/asheducation-2006.1.432

Published: 2006

Journal Articles

Perioperative Evaluation of Bleeding Diathesis

Lawrence L.K. Leung

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 457–461.

https://doi.org/10.1182/asheducation-2006.1.457

Published: 2006

Journal Articles

The Role of Immunomodulation in the Management of Factor VIII Inhibitors

David Lillicrap

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 421–425.

https://doi.org/10.1182/asheducation-2006.1.421

Published: 2006

Journal Articles

New Perspectives in Hemophilia Treatment

Craig M. Kessler

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 429–435.

https://doi.org/10.1182/asheducation-2005.1.429

Published: 2005

NARROW

New therapies for von Willebrand disease

Perioperative management of patients with von Willebrand disease

New advances in the diagnosis of von Willebrand disease

Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy

What have we learned from large population studies of von Willebrand disease?

Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors

Acquired bleeding disorders in the elderly

Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses

Lasting power of new clotting proteins

Clinical and laboratory diagnosis of VWD

von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy

The hemophilias and their clinical management

Biological Rationale for New Drugs in the Bleeding Disorders Pipeline

What is the Evidence for the Use of Immunomodulatory Agents to Eradicate Inhibitory Antibodies in Patients with Severe Hemophilia A Who Have Previously Failed to Respond to Immune Tolerance Induction?

Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A

Optimizing treatment of von Willebrand disease by using phenotypic and molecular data

Acquired Factor VIII Inhibitors: Pathophysiology and Treatment

Perioperative Evaluation of Bleeding Diathesis

The Role of Immunomodulation in the Management of Factor VIII Inhibitors

New Perspectives in Hemophilia Treatment

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only